'Epigenetic landscape' is protective in normal aging, impaired in Alzheimer's disease

March 5, 2018, Perelman School of Medicine at the University of Pennsylvania
Coronal section of human brain indicating the lateral temporal lobe (red circle) used in this study. Credit: Coronal section of human brain indicating The lab of Shelley Berger, PhD, Perelman School of Medicine, University of Pennsylvania

Although certain genetic variants increase the risk of Alzheimer's disease (AD), age is the strongest known risk factor. But the way in which molecular processes of aging predispose people to AD, or become impaired in AD remains a mystery. A team of researchers from the Perelman School of Medicine at the University of Pennsylvania, publishing in Nature Neuroscience this week, profiled the epigenomic landscape of AD brains, specifically in one of the regions affected early in AD, the lateral temporal lobe. They compared these to both younger and elderly cognitively normal control subjects. The team described the genome-wide enrichment of a chemical modification of histone proteins that regulates the compaction of chromosomes in the nucleus (called acetylation of lysine 16 on histone H4, or H4K16ac for short).

Changes to the way H4K16ac is modified along the genome in disease versus normal aging brains may signify places for future drug development. Because changes in H4K16ac govern how genes are expressed, the location and amount of epigenetic alterations is called the "epigenetic landscape."

"This is the first time that we have been able to look at these relationships in human tissue by using donated postmortem tissue from the Penn Brain Bank," said Shelley Berger, PhD, a professor of Cell and Developmental Biology in the Perelman School of Medicine and a professor of Biology in the School of Arts and Sciences. "Our results establish the basis for an epigenetic link between aging and Alzheimer's disease."

Berger, also the director of the Penn Epigenetics Institute, Nancy Bonini, PhD, a professor of Biology, and Brad Johnson, MD, PhD, an associate professor of Pathology and Laboratory Medicine, are co-senior authors of the new study.

H4K16ac is a key modification in human health because it regulates cellular responses to stress and to DNA damage. The team found that, while normal aging leads to increasing H4K16ac in new positions along the genome and an increase in where it is already present, in great contrast, AD entails losses of H4K16ac in the proximity of genes linked to aging and AD. In addition, the team discovered an association between the location of H4K16ac changes and genetic variants identified in prior AD genome-wide association studies.

A three-way comparison of younger, older, and AD brain tissue revealed a specific class of H4K16ac changes in AD compared to normal age-established changes in the brain. This finding indicates that certain normal aging changes in the epigenome may actually protect against AD and when these goes awry, a person may become predisposed to AD.

"These analyses point to a new model of Alzheimer's disease. Specifically it appears that AD is not simply an advanced state of normal aging, but rather dysregulated aging that may induce disease-specific changes to the structure of chromatin - the combination of and DNA." said first author Raffaella Nativio, PhD, a postdoctoral fellow in Berger's lab.

Accumulation of intercellular amyloid plaques and neurofibrillary tangles are the two hallmarks of AD that drive the death of neurons and the corresponding loss of cognitive abilities. However, expression of plaques and tangles is very late in the development of AD, while epigenome alterations might occur much earlier and represent targets to attack with medications.

The authors emphasized that this study does not suggest a cure for AD, but rather the possibility of finding ways to prevent nerve cell death and enhance the quality of aging. Their upcoming experiments aim to discover the physiological changes that cause the decrease of H4K16ac specifically in AD brains, but not in normal-aged brains.

Explore further: Genome wide association study of epigenetic aging rates in blood reveals a critical role for TERT

More information: Dysregulation of the epigenetic landscape of normal aging in Alzheimer's disease, Nature Neuroscience (2018). nature.com/articles/doi:10.1038/s41593-018-0101-9

Related Stories

Genome wide association study of epigenetic aging rates in blood reveals a critical role for TERT

February 2, 2018
Researchers from several institutions, including, UCLA, Boston University, Stanford University and the Institute for Aging Research at Hebrew SeniorLife, analyzed blood samples from nearly 10,000 people to find that genetic ...

Higher brain glucose levels may mean more severe Alzheimer's

November 6, 2017
For the first time, scientists have found a connection between abnormalities in how the brain breaks down glucose and the severity of the signature amyloid plaques and tangles in the brain, as well as the onset of eventual ...

Genetic variant accelerates normal brain aging in older people by up to 12 years

March 15, 2017
Columbia University Medical Center (CUMC) researchers have discovered a common genetic variant that greatly impacts normal brain aging, starting at around age 65, and may modify the risk for neurodegenerative diseases. The ...

Genes associated with resilience against brain pathology identified

April 25, 2017
The pathologies (damage) in the brain that stroke, Alzheimer's disease and other neurological conditions cause in older adults only partially explain the memory loss, reduced reasoning ability and other cognitive impairments ...

New Alzheimer's animal model more closely mimics human disease

December 4, 2017
By injecting human Alzheimer's disease brain extracts of pathological tau protein (from postmortem donated tissue) into mice with different amounts of amyloid-β (Aβ) plaques in their brains, researchers from the Perelman ...

Recommended for you

A new approach for finding Alzheimer's treatments

September 11, 2018
Considering what little progress has been made finding drugs to treat Alzheimer's disease, Maikel Rheinstädter decided to come at the problem from a totally different angle—perhaps the solution lay not with the peptide ...

Study prevents cognitive decline in older blacks with memory loss

September 10, 2018
With nearly twice the rate of dementia as whites, blacks are at a higher risk for developing diseases like Alzheimer's, but there has been little research on how to reduce this racial health disparity. A new study in black ...

Excessive daytime sleepiness linked with brain protein involved in Alzheimer's disease

September 6, 2018
Analysis of data captured during a long-term study of aging adults shows that those who report being very sleepy during the day were nearly three times more likely than those who didn't to have brain deposits of beta amyloid, ...

Study shows how exercise generates new neurons, improves cognition in Alzheimer's mouse

September 6, 2018
A study by a Massachusetts General Hospital (MGH) research team finds that neurogenesis -inducing the production of new neurons—in the brain structure in which memories are encoded can improve cognitive function in a mouse ...

Novel strategy shows promise for earlier detection of Alzheimer's disease

September 4, 2018
Finding an effective way to identify people with mild cognitive impairment who are most likely to go on to develop Alzheimer's disease has eluded researchers for years. But now, a team of researchers led by David Loewenstein, ...

Dementia symptoms peak in winter and spring, study finds

September 4, 2018
Adults both with and without Alzheimer's disease have better cognition skills in the late summer and early fall than in the winter and spring, according to a new study published this week in PLOS Medicine by Andrew Lim of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.